歌礼制药:将在第62届EASD年会上汇报用于治疗肥胖症的ASC36_35 FDC临床前数据

格隆汇
Yesterday

歌礼制药在港交所公告,公司董事会宣布将在意大利米兰举行的第62届欧洲糖尿病研究协会(EASD)年会上以简短口头讨论形式报告用于治疗肥胖症的ASC36_35 FDC,即ASC36(一款多肽胰淀素受体激动剂)与ASC35(一款多肽GLP-1R/GIPR激动剂)的每月一次注射复方制剂的临床前数据。数据显示,在饮食诱导肥胖(DIO)动物模型中,与eloralintide和替尔泊肽联合给药相比,该药物展现出更优越的减重效果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10